[Checkpoint inhibitors-indications and application in melanoma patients].

Lamos, Cristina; Hunger, Robert (2020). [Checkpoint inhibitors-indications and application in melanoma patients]. Zeitschrift für Rheumatologie, 79(8), pp. 818-825. Springer-Medizin-Verlag 10.1007/s00393-020-00870-8

[img]
Preview
Text
393_2020_Article_870.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (450kB) | Preview

Since its introduction in 2011 the checkpoint inhibitor ipilimumab, has revolutionized the whole of oncology. After this first major step more checkpoint inhibitors, such as the PD‑1 antibodies nivolumab and pembrolizumab have been developed. The results are groundbreaking, especially in advanced malignant melanoma, which only a few years ago led to certain death in most cases after only a few months. Currently, the application of checkpoint inhibitors has been extended to many more tumor entities, with very promising results.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Lamos, Cristina and Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0340-1855

Publisher:

Springer-Medizin-Verlag

Language:

German

Submitter:

Sandra Nyffenegger

Date Deposited:

14 Dec 2020 16:12

Last Modified:

29 Mar 2021 11:35

Publisher DOI:

10.1007/s00393-020-00870-8

PubMed ID:

32926216

Uncontrolled Keywords:

CTLA-4 blocker Immuno-oncology Melanoma therapy PD-1 inhibitor System therapy

BORIS DOI:

10.7892/boris.148357

URI:

https://boris.unibe.ch/id/eprint/148357

Actions (login required)

Edit item Edit item
Provide Feedback